Drug intelligence / Profile preview

MD 2009

Development stage: Preclinical
Lead developer: AusBio
Modality: Small Molecules

Overview

MD 2009 is a preclinical-stage small molecule neuraminidase inhibitor being developed by AusBio for the treatment of influenza. While traditional neuraminidase inhibitors like oseltamivir target the enzyme's active site to prevent viral release, MD 2009 is characterized by a distinct mechanism of action compared to existing therapies. This novel approach is intended to provide efficacy against influenza strains that may have developed resistance to current standard-of-care treatments. The project is currently undergoing preclinical evaluation to determine its safety and therapeutic potential.

Other names: MD2009-AusBio-Neuraminidase-small molecule-InfluenzaMD-2009-AusBio-Neuraminidase-small molecule-InfluenzaMD 2009-AusBio-Neuraminidase-small molecule-Influenza

Targets

Neuraminidase

Beyond the preview

Go deeper on MD 2009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MD 2009.

Explore the full profile